Top Story

HHS funds further development of two rapid, point-of-care influenza tests

October 1, 2014

Alere Inc. and InDevR Inc. have each entered into a contract with the US Department of Health and Human Services to further development on two influenza virus tests, according to a press release.

Alere Inc. will receive $12.9 million under a 3.5-year contract to further develop iNAT, a rapid, inexpensive molecular test that could indicate whether a patient has seasonal influenza A or B virus within 15 minutes. The company is responsible for conducting clinical trials to support FDA 510(K) clearance and a Clinical Laboratory Improvement Amendments waiver for iNAT.

FDA News

FDA approves new clinical targets for Luminex xTAG GI pathogen panel

October 1, 2014
Luminex has received FDA approval to add three new targets to its xTAG Gastrointestinal Pathogen Panel, including adenovirus 40/41, Entamoeba histolytica and Vibrio
Meeting News Coverage

Thrombocytopenia common among Romanian patients with HCV

October 1, 2014
NEW YORK — Thrombocytopenia had a high prevalence among Romanian patients with chronic hepatitis C virus infection, according to data presented at the AASLD/EASL…
In the Journals

Rapid response, inspector experience critical in E. coli outbreaks in UK

October 1, 2014
A review of Escherichia coli O157 outbreaks in the United Kingdom from the 1980s to 2013 highlighted two key lessons: Rapid response to an outbreak is crucial, and…
More News Headlines »
CME
figure

Pediatric Perspectives on the Management of Diarrhea in Infants and Children - Monograph

This activity is supported by an educational grant from Lupin Pharmaceuticals, Inc.

An estimated 1.2 million cases of giardiasis and 750,000 cases of cryptosporidiosis occur in the United States…
More »
Meeting News Coverage Video
figure

Robust antibiotic pipeline may require new thinking

September 20, 2014
WASHINGTON, D.C. — ICAAC 2014 keynote speaker John H. Rex, MD, senior vice president and head of infection…
More »
CME
figure

HCV Consults: Volume 1, Number 1

This activity is supported by educational grants from AbbVie and Genentech.

Physicians seldom experience a paradigm shift in disease management as great as that transpiring in HCV therapy. With…
More »